

Bebtelovimab appears reliable for COVID-19 during Omicron epoch

September 20 2022



For high-risk patients with mild-to-moderate COVID-19 during the

Omicron epoch, bebtelovimab seems to be a reliable treatment option, according to a study published online Sept. 17 in the *Journal of Infectious Diseases*.

Raymund R. Razonable, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a [retrospective cohort study](#) involving 3,607 [high-risk patients](#) to examine the effectiveness of bebtelovimab in real-world settings. A total of 2,833 patients received bebtelovimab and 774 received nirmatrelvir-ritonavir.

The researchers found that compared with nirmatrelvir-ritonavir, bebtelovimab was used more often for treatment of COVID-19 among [older patients](#), immunosuppressed patients, and those with multiple comorbidities. The rates of progression to severe disease by 30 days after treatment were not significantly different after bebtelovimab versus nirmatrelvir-ritonavir treatment (1.4 versus 1.2 percent). The rate of admission to the [intensive care unit](#) was comparable between the groups (0.5 and 0.3 percent for those receiving bebtelovimab and nirmatrelvir-ritonavir treatment, respectively).

"This study gives us confidence that bebtelovimab is reliable for the treatment of high-risk patients during this Omicron epoch characterized by increasingly new variants, and gives us another tool in the effort against COVID-19," Razonable said in a statement.

Two authors disclosed financial ties to the pharmaceutical industry.

More information: Raymund R Razonable et al, Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch, *The Journal of Infectious Diseases* (2022). [DOI: 10.1093/infdis/jiac346](https://doi.org/10.1093/infdis/jiac346)

Copyright © 2022 [HealthDay](#). All rights reserved.

Citation: Bebtelovimab appears reliable for COVID-19 during Omicron epoch (2022, September 20) retrieved 6 May 2024 from <https://medicalxpress.com/news/2022-09-bebtelovimab-reliable-covid-omicron-epoch.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.